# A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

> **NCT01794000** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 341 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Prasugrel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01794000
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-04
- **Primary completion:** 2015-07
- **Final completion:** 2015-12
- **Target enrollment:** 341 (ACTUAL)
- **Why stopped:** The study is being terminated for lack of efficacy.
- **Last updated:** 2019-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01794000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01794000, "A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01794000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*